177 Lu has been used as a radiotherapy agent for a long time in the literature 53, and more recently has been chelated to small molecule peptides or prostate-specific membrane antigen (PSMA) inhibitors for targeted radiotherapy of neuroendocrine tumors and prostate cancers. Here, FOLH1 is linked to neuroendocrine neoplasm.